Marc Gitzinger is CEO and co-founder of BioVersys in Basel (Switzerland) and has raised over $70 mio in equity financing and secured over $30 mio in non-dilutive funding. He has also established several important partnerships with a Big Pharma and other development organizations.
Marc has over 10 years of experience in the biotech industry, having launched a university spin-off in the field of antimicrobial resistance and growing it into a multi-asset clinical stage company. Some of these assets will address significant unmet medical needs in infectious conditions such as tuberculosis and hospital acquired Acinetobacter infections.
He is also President of the Board of the BEAM Alliance, a European association representing over 70 European and international SMEs active in antimicrobial research and development and Board member of AMR Industry Alliance. Marc is a young thought leader in the field of antimicrobial research and development. He is passionate about next generation antimicrobial therapies and leads a highly motivated team striving to bring life-saving antimicrobial therapies to patients in need. He is also co-author on several high ranked scientific publications and patents in the field.
There is a huge and fast-growing unmet need in treating bacterial infections and AMR but raising funds for new antibiotics has been next to impossible. The commercial backdrop for new antibiotics remains extremely challenging – the better the antibiotic the less frequently it gets used to avoid development of resistance. As a result, VC investors have remained on the sidelines.